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Proper tissue vascularization is vital for cellular function as it delivers oxygen, nutrients, hormones, and
immune cells and helps to clear cellular debris and metabolic waste products. Tissue angiogenesis occurs
to satisfy energy requirements and cellular sensors of metabolic imbalance coordinate vessel growth. In
this regard, the classical pathways of the unfolded protein response activated under conditions of ER stress
have recently been described to generate angiomodulatory or angiostatic signals. This review elaborates on
the link between angiogenesis and ER stress and discusses the implications for diseases characterized by
altered vascular homeostasis, such as cancer, retinopathies, and atherosclerosis.Introduction
Chemicals, proteins, and nutrients can generally only cross
plasmamembranes when dissolved in aqueous solution. Hence,
the need for a proximal delivery system arose as body plans of
multicellular organisms evolved and simple diffusion was no
longer efficient over increasingly greater distances. The last two
decades have witnessed a surge in our understanding of themo-
lecular and cellular mechanisms governing blood vessel growth
(Carmeliet and Jain, 2011). There has been growing interest in
how energy metabolism and enzymes derived from glycolytic
andO2-dependent energeticpathwayscontribute to theelabora-
tion of vascular plexuses (De Bock et al., 2013b; Schoors et al.,
2014) and howcarbohydratemetabolites and fatty acid oxidation
influenceangiogenesis (Sapiehaet al., 2008;Schoors et al., 2015;
Sonveaux et al., 2012). The later path of exploration placed focus
on mitochondria. Another critical organelle that has received
considerably less attention in the field of angiogenesis is the
ER. In this regard, evidence is accumulating that the highly evolu-
tionarily conserved pathways of the unfolded protein response
(UPR), which are either triggered secondary to perturbations of
the ER or independently, can modulate vascular growth.
The folding of proteins in the ER represents an energy-inten-
sive process and a key cellular checkpoint that is fine-tuned by
pathways of the UPR. Their interplay allows complex organisms
to rapidly adapt to an increase in protein demand and synthesis
(thus folding) (Harding et al., 2001) or maintain adequate quality
control over new secreted or transmembrane proteins (Ryoo
et al., 2007). Originally described as a consequence of misfolded
protein accumulation, sustained activation of the UPR during
nutrient deprivation and hypoxia limits cellular processes to
bare essentials and thus prevents adequate crosstalk of the
affected cell with its environment. In the context of angiogenesis,
ER stress may be particularly important in a cell’s initial adapta-
tion to insufficient metabolic supply or in an energy crisis (such
as during hypoxia/ischemia or nutrient deficiency and lower
ATP production) (Deng et al., 2013; Pereira et al., 2014; Binet
et al., 2013). These stressors can be alleviated through the for-
mation of neovessels within the affected tissue.
The present review addresses the emerging evidence impli-
cating pathways of the UPR in angiogenesis and their impact560 Cell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc.on vascular pathologies, such as vaso-proliferative disorders
of the eye, cancer, and atherosclerosis. The contribution of ER
stress to vascular regeneration and tissue segregation is also
discussed, as is prospective therapeutic targeting of the UPR
to modulate angiogenesis.
Cellular Roles for the UPRPathways inMammalian Cells
Pathways of ER stress have been thoroughly conserved
throughout evolution, especially in metazoans (Hollien, 2013).
This attests to the UPR’s fundamental role in cellular adaption
to environmental and developmental stressors. As organisms
evolved, growing larger and more complex, there was a
parallel increased demand for protein production, folding, and
quality control. Local metabolic satiation in higher order verte-
brates called for closed blood circulatory networks to ensure
efficient delivery and exchange of gases, nutrients, and metab-
olites to guarantee pairing of metabolic supply to anabolic
requirements.
The mechanisms of quality control in the ER during protein
production rely on a sophisticated interplay between various
arms of the UPR to ultimately ensure proper protein production.
For example, mammals employ pathways of the UPR to adapt to
new physiological conditions, such as increased blood sugar,
through which the UPR can prompt differentiation and mainte-
nance of secretory cells, such as pancreatic beta islets cells (Lip-
son et al., 2006; Rosenfeld et al., 2006).
Production and export of proteins is a highly energy-intensive
process. Hence, several cellular stressors that compromise the
energetic status of a cell, such as inadequate supply of amino
acids (nutrients) or oxygen (Binet et al., 2013), depletion of ER
luminal Ca2+, accumulation of reactive oxygen species, or
mutated polypeptides, can result in the buildup of unfolded
proteins in the lumen of the ER and will trigger the UPR (Walter
and Ron, 2011). The three main ER transmembrane sensors
that elicit the UPR are the protein kinase RNA-like ER kinase/
activating transcription factor 4 (PERK-ATF4) axis (Figure 1A),
inositol-requiring enzyme-1a/X-box binding protein 1 (IRE1a/
XBP1) axis (Figure 1B), and the activating transcription factor 6
(ATF6) axis (Figure 1C). Molecular insight into these pathways
has been reviewed extensively elsewhere (Cao and Kaufman,
Figure 1. Pathways of the UPR
(A) The PERK axis. Release of GRP78 upon buildup of misfolded proteins, inadequate glucose levels, or other stressors enable dimerization of PERK and its
consequent autophosphorylation. Activated PERK then phoshorylates the alpha subunit of eIF2, leading to global translation arrest. Transcripts with alternative
upstream open reading frames, such as ATF4, are then preferentially translated. Expression of ATF4 can lead to induction of CHOP, in turn reversing translational
repression by activating GADD34. Upon severe and sustained ER stress, CHOP promotes apoptosis.
(B) The IRE1a axis. After dissociation of GRP78 from IRE1a in the luminal portion of the ER, IRE1a oligomerizes and autophosphorylates. This triggers outcomes,
such as endoribonuclease-driven degradation of mRNAs or microRNAs, by RIDD activity and splicing of an intron in the XBP-1 gene. Splicing of XBP-1 generates
an active transcription factor that induces genes with various cellular functions, such as ER membrane phospholipid biogenesis. Alternatively, the kinase activity
of IRE1a can activate a TRAF2-ASK1-JNK1 pro-apoptotic program.
(C) The ATF6 axis. Upon dissociation of GRP78, ATF6 translocates to the Golgi and is cleaved by S1P and S2P proteases. The ensuing N-terminal fragment of
ATF6 is then shuttled to the nucleus, where it binds the ERSE promoter regions in genes, such as GRP78, to restore ER homeostasis.
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briefly outlined below.
The PERK Pathway
Secondary to accumulation of misfolded proteins, the type I
serine/threonine kinase PERK is activated after dissociation of
glucose-regulated protein 78 (GRP78, an abundant ER chap-
erone also named BiP [binding immunoglobulin protein]) from
its luminal domain (Bertolotti et al., 2000). This provokes the acti-
vation of PERK through homomultimerization and trans-auto-
phosphorylation (Walter and Ron, 2011). Activated PERK then
attenuates protein synthesis by phosphorylating the alpha sub-
unit of the eukaryotic initiation factor eIF2 (Harding et al., 1999,
2000) (Figure 1A). The repression of translation is typically tran-
sient as subsets of mRNAs, such as ATF4 (Lu et al., 2004),
ATF5 (Watatani et al., 2008), growth arrest and DNA damage-
inducible protein (GADD34) (Lee et al., 2009), and CCAAT/
enhancer binding protein homologous protein (CHOP) (Palam
et al., 2011), escape this mechanism of translational inhibition
by possessing unconventional 50 open reading frames (ORFs).
Restoration of protein synthesis occurs through the association
of GADD34 with the catalytic subunit of protein phosphatase 1
(PP1) and consequent dephosphorylation of eIF2a (Ma and Hen-
dershot, 2003). Thus, activation of GADD34/PP1 represents a
feedback mechanism to promote recovery from protein synthe-
sis inhibition when the physiological context requires (Novoa
et al., 2001). Similarly, the bZIP transcription factor ATF4 canaid cellular function by promoting amino acid biosynthesis (Har-
ding et al., 2003), contributing to an anti-oxidative response,
facilitating autophagy (Rzymski et al., 2010) and transcribing
ER chaperones, such as GRP78 (Luo et al., 2003). Alternatively,
another primary transcriptional target of ATF4 is the bZIP tran-
scription factor CHOP, which controls expression of several
pro-apoptotic factors, such as BCL2-like 11 (apoptosis facili-
tator; Bim), tribbles-related protein 3 (TRB3) (Ohoka et al.,
2005), and death receptor 5 (DR5) (Yamaguchi and Wang,
2004), and blocks anti-apoptotic B cell CLL/lymphoma 2
(BCL-2) (McCullough et al., 2001). Hence, when required, the
PERK pathway has the propensity to drive apoptosis.
The IRE1a Pathway
A second branch of the UPR is regulated through the type I trans-
membrane protein IRE1a, which possesses both a serine/threo-
nine kinase domain and a distinct endoribonuclease domain on
its cytosolic terminus (Zhou et al., 2006) (Figure 1B). IRE1a is
thought to be the most ancient and conserved branch of the
UPR. It has a similar ER luminal domain to PERK that binds the
chaperone protein GRP78 when in a resting state (Bertolotti
et al., 2000). Accretion of unfolded proteins on the luminal side
of the ER or other stressors provoke dissociation of GRP78
from IRE1a. Consequently, this allows dimerization or multimeri-
zation of IRE1a and leads to its trans-autophosphorylation and
activation (Korennykh et al., 2009; Liu et al., 2002) (Figure 1B).
Alternatively, in yeast, misfolded proteins can directly bind toCell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc. 561
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analogous to the major histocompatibility complex (MHC-I)
peptide-binding groove. This alternative mode of detection of
unfolded proteins promotes association with aggregation-prone
peptides and leads to oligomerization/activation of IRE1 and
thus represents an additional level of regulation of the UPR
(Gardner and Walter, 2011).
Via its endoribonuclease domain, activated IRE1a has the pro-
pensity to cleave and degrade selected mRNAs (Hollien and
Weissman, 2006) and microRNAs (miRNA) (Upton et al., 2012)
in a process termed regulated IRE1-dependent decay (RIDD).
This mechanism is thought to specifically target mRNAs encod-
ing proteins that traverse the ER-Golgi secretory pathway
(Hollien and Weissman, 2006a) and consequently reduce trans-
lation and folding.
An alternativemechanism of action for IRE1a involves excision
of a 26-base pair (bp) intron in the mRNA-encoding transcription
factor X-box binding-protein (XBP-1); this yields an active tran-
scription factor (XBP-1 s) that regulates the expression of sub-
sets of genes involved in protein folding. These include the
Hsp40-like ATPase chaperones (ER-localized DnaJ homolog
[ERdj4], the DnaJ protein p58IPK, and DnaJ protein homolog
9/HEDJ) and chaperones, such as EDEM, involved in ER-associ-
ated protein degradation (ERAD) (Lee et al., 2003), chaperones
contributing to disulfide-bond formation, such as protein disul-
fide isomerase (PDI-P5) (Lee et al., 2003), or genes involved in
vesicular trafficking and transport, such as Sec23a and b (Sriburi
et al., 2007). Together, transcription of XBP-1-dependent genes
relieves ER stress by improving the protein-folding capacity of
the ER, increasing ER membrane biosynthesis, or stimulating
polypeptide retrotranslocation and degradation by the proteaso-
mal ubiquitin pathway.
IRE1a is also equipped with a kinase domain that, through
interaction with the adaptor protein TNF receptor-associated
factor 2 (TRAF2), promotes nuclear factor-kappa B (NF-kB) acti-
vation and triggers an inflammatory response (Hu et al., 2006).
Similarly, association of IRE1a with TRAF2 can phosphorylate
Janus N-terminal kinase (JNK) and further contribute to a pro-
inflammatory response (Urano et al., 2000). Together, these
studies suggest that IRE1a bridges ER stress to an inflammatory
response.
The ATF6 Pathway
In a third parallel pathway, ER stress triggers dissociation of
GRP78 from ATF6, a type II ER transmembrane protein. This
leads to its relocalization to the Golgi apparatus, where it be-
comes processed by Site-1 protease (S1P) and S2P protease
via a mechanism termed regulated intramembrane proteolysis
(RIP) and generates ATF6f (p50) (Ye et al., 2000) (Figure 1C).
ATF6f is a bZIP protein that drives expression of genes involved
in ER homeostasis, through recognition of the ER stress element
(ERSE) in the promoter region of grp genes, such as GRP78
(Yoshida et al., 1998). Thus, ATF6 confers protection against
ER stress, especially in a chronic setting (Yamamoto et al., 2010).
Basic Mechanisms of Angiogenesis
In order to appreciate the interplay between cellular ER stress
and tissue vascularization, we will very briefly outline the primary
processes at play during formation of vascular networks. During
embryogenesis, a functional circulatory system is the first of the562 Cell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc.major systems to develop. The initial mammalian primitive
vasculature arises from angiogenic clusters containing heman-
gioblasts, which yield precursors of hematopoietic cells at their
center and endothelial cells at their periphery (Tavian and Pe´ault,
2005). The formation of vessels then ensues by successive
waves of vasculogenesis and angiogenesis. In vasculogenesis,
blood vessels form de novo from cells called angioblasts in the
mesoderm of individual organs (Risau, 1997; Risau and Flamme,
1995). Organ-specific vascular networks subsequently become
connected to major blood vessels. Angiogenesis occurs at later
stages of embryogenesis when existing vessels sprout endothe-
lial cells into the developing tissue, establish perfusable luminal
tubes, and anastomose to form a functional circulatory system.
Maturation of vascular plexus then proceeds through recruit-
ment of pericytes and vascular smooth muscle cells, which sta-
bilize vessels and regulate blood flow.
Sprouting endothelial cells can be among the most invasive
cells of the body as they need to enter andmigrate through target
tissue. Sprouting angiogenesis is triggered by gradients of
growth factors, such as VEGF, originating from the tissue being
vascularized. Once the basement membrane is broken down
through a series of events, including metalloproteinase-medi-
ated digestion (Johnson et al., 2004; Stratman et al., 2009),
specialized vascular cells at the leading edge of the nascent
vessel, called tip cells (Figure 2), advance and grow. Tip cells
sense and integrate the environment of the tissue and ultimately
dictate whether to proceed, turn, or collapse. This is achieved via
the interplay of attractive or repulsive guidance cues (Sema-
phorin, Netrins, Slits, VEGF, and Ephrins) and their receptors
(Neuropilins, Plexins, Unc5, deleted in colorectal carcinoma
[DCC], VEGFR2, roundabout [Robo], and Eph) (Figure 2B) (Larri-
ve´e et al., 2009).
Neovessels then grow through proliferation of stalk cells pre-
sent in the wake of advancing tip cells. Subsequently to the acti-
vation of VEGFR-2 by VEGF, tip cells sprout and upregulate the
Notch ligand Delta-like ligand 4 (Dll4) (Hellstro¨m et al., 2007;
Lobov et al., 2007; Suchting et al., 2007) (however possibly
modestly; Benedito et al., 2012). Dll4 on tip cells laterally inhibit
sprouting of the neighboring stalk cells through upregulation of
VEGR1, a VEGF decoy receptor. This assures that a selected
endothelial cell leads themigration front and inhibits idle multipli-
cation of vascular tip cells. The cellular and molecular mecha-
nisms that lead to sprouting angiogenesis and vessel maturation
have been thoroughly described in several comprehensive re-
views on the subject (De Bock et al., 2013a; Goveia et al.,
2014; Potente et al., 2011), and a concise overview is provided
in Figure 2.
The UPR and Embryonic Vascularization
Evidence supporting a role for UPR signaling in vascular devel-
opment originates from genetic loss-of-function studies of the
IRE1a pathway as PERK/ (Zhang et al., 2002) and ATF6/
(both ATF6a/ or ATF6b/) (Yamamoto et al., 2007) mice
survive gestation. IRE1a/ embryos display broad and severe
developmental deficiencies and generally die after 12.5 days
of gestation (Zhang et al., 2005). This embryonic lethality is
thought to occur through compromised expression of placental
VEGF in IRE1a/ mice, which leads to a consequent reduction
in the blood space of the labyrinth layer of the placenta (Iwawaki
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Figure 2. Basic Mechanisms in
Angiogenesis
(A–C) A schematic depicting the various pro-
cesses that regulate angiogenesis.
(A) Glycolytic intermediates (lactate, succinate,
and others), as well as glycolytic enzymes,
such as 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 (PFKFB3), are essential for
vascular sprouting and link metabolism to angio-
genesis (De Bock et al., 2013a, 2013b).
(B) VEGF binds to VEGFR2 to stimulate neovessel
outgrowth. VEGFR1 is believed to act as a decoy
receptor for VEGF by minimizing sprouting.
Notch-Dll4-Jagged1 dictates tip-cell positioning
at the vascular front, where Jagged1 favors filo-
podial expansion, while Dll4 favors stalk cells.
Guidance molecules (netrins, semaphorins) and
their receptors (Unc5b, Neuropilin-1 [NRP-1])
attract or repulse neovessels. Netrin-1 can also
activate adenosine A2B receptor (AA2BR) on
macrophages/microglia to induce VEGF secretion
and tip-cell formation (Binet et al., 2013).
(C) Low oxygen tension stabilizes the alpha sub-
unit of hypoxia-inducible factors (HIFs; HIF1a and
HIF-2a) by limiting HIF hydroxylation by prolyl
hydroxylase (PHDs). Under normoxic conditions,
HIF-a is rapidly degraded by the proteasome.
HIFs coordinate expression of a plethora of pro-
angiogenic modulators, such as EPO, VEGF,
Angiopoietin 2 (ANGPT2), and MMPs, among
several more.
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nutrients at the mother-fetus interface. Conversely, placental
levels of VEGF are normal in XBP-1/ mice (Iwawaki et al.,
2009), yet contrary to IRE1a/ embryos, XBP-1-deficient em-
bryos themselves show deficient blood vessel development
and later stalled retinal vascularization (Zeng et al., 2013).
Together, these data suggest that IRE1a and XBP-1 might carry
out distinct roles in fetal development by controlling angiogen-
esis in the placenta or in the embryo and highlight a role for
UPR in embryonic vascularization.
Pathways of the UPR Modulate VEGF Production
Insufficient vascular supply causes hypoxia, nutrient deprivation,
and consequently lowered ATP production. These factors are
also commonly associated with failure of protein folding, ER
stress (Deng et al., 2013; Pereira et al., 2014), and UPR signaling
is readily triggered in ischemic tissues (Binet et al., 2013; Wang
et al., 2012). In response to tissue hypoxia, angiogenic programs
are activated to remedy the perceived lack of oxygen and
metabolites. This occurs through production of several oxy-
gen-sensitive factors that favor vessel growth, such as VEGF
and erythropoietin (Epo).
In physiological embryonic angiogenesis, as in pathological
adult neovascularization such as tumor neovascularization or
neovascular diseases of the retina (see below), the best-charac-
terized pro-angiogenic factor is VEGFA165 (VEGF). Transcrip-
tion factors from all three arms of the UPR (ATF4, spliced
XBP-1, and cleaved ATF6) have consensus sites on the promoter
region of VEGF and have been shown to bind and drive its tran-
scription (Ghosh et al., 2010) (Figure 3A). XBP-1s has the capac-
ity to bind to at least two regions in the VEGF promoter: 1,9 and
5,2 kb upstream of the transcription start codon (Pereira et al.,2010). In addition, the promoter region of VEGF has four distinct
amino acid response elements (AAREs), where ATF4 can bind,
and ATF4-dependant transcription has been demonstrated,
following homocysteine treatment or exposure to oxidative
stressors, such as arsenite (Roybal et al., 2005) (Figure 3A).
Moreover, oxidized phospholipids, which are hallmarks of
atherosclerotic lesions and drusen deposits in age-related mac-
ular degeneration (AMD), trigger VEGF transcription and transla-
tion in several endothelial cell lines via a mechanism involving
PERK-Nuclear factor (erythroid-derived 2)-like 2 (NRF2) and
ATF4 (Afonyushkin et al., 2010). PERK-mediated phosphoryla-
tion of the bZIP transcription factor NRF2 triggers its dissociation
from KEAP and its nuclear translocation (Cullinan et al., 2003).
NRF2 is part of a separate sensing pathway termed the electro-
philic stress response (ESR) that protects cells against oxidative
stress (Xu et al., 2014), suggesting that reactive oxidative stress
pathways, which activate NRF2 can cooperate with the UPR to
trigger a pro-angiogenic response. Induction of theUPRby thap-
sigargin, which depletes ER Ca2+ stores, has also been shown to
stabilize VEGF mRNA through a mechanism involving AMP-acti-
vated protein kinase (AMPK) (Pereira et al., 2010). Collectively, all
three arms of the UPR enhance VEGF expression.
Additional Pro-angiogenic Modulators Regulated by
the UPR
The majority of studies linking the UPR to angiogenic cascades
have thus far focused on VEGF, yet other factors with vaso-
modulatory properties are modulated by the UPR. For example,
ATF4 can transcriptionally modulate interleukin (IL)-8 in various
human aortic endothelial cell lines in response to oxidized phos-
pholipids (Gargalovic et al., 2006). IL-8 is a pro-angiogenic cyto-
kine that enhances endothelial cell proliferation and capillaryCell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc. 563
Figure 3. UPR Pathways Regulate Angiogenic Signaling
(A) UPR drives pro-angiogenic signaling: the three branches of the UPR induce expression of VEGFmRNA. HIF-1a is stabilized by UPR signaling and cooperates
with UPR for VEGF induction. TSS, transcription start site.
(B) UPR also stimulates anti-angiogenic signaling. (Left) Oxidative stress triggers the UPR and activation of the CHOP transcription factor. CHOP binds and
inhibits the promoter of pro-angiogenic effector eNOS. (Right) Upon ER stress, CREB3L1 dissociates from the ER, translocates to the Golgi, and is cleaved by
regulated intermembrane proteolysis (RIP) to yield a potent transcription factor. Processed CREB3L1 binds and inhibits the promoters of pro-angiogenic genes,
such as pleiotrophin (PTN) or FGFB1, that are required for tumor growth.
(C) Splicing of XBP-1 mediated by KDR/VEGFR2 leads to enhanced EC proliferation. Interaction between the C terminus of KDR and unspliced XBP-1 and IRE1a
drives XBP-1 splicing upon VEGF stimulation. Spliced XBP-1 then drives endothelial proliferation through the Akt/GSK/b-catenin pathway.
(D) Activation of PERK/ATF6 signaling by the VEGF/mTOR/Akt pathway induces EC survival. VEGF promotes endothelial survival through PLCg-mTORC1-
dependent induction of PERK and ATF6.
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while decreasing endothelial cell apoptosis (Li et al., 2003).
Similarly, using genome-wide microarrays, Pereira et al. (2010)
reported upregulation of IL-8 and VEGF, as well as other pro-
angiogenic mediators, such as basic fibroblast growth factor
and angiogenin, following experimental in vitro induction of ER
stress with thapsigargin. Interestingly, the induction of many of
these angiogenic factors was of similar magnitude or even
greater following ER stress than in hypoxic (1% 02) or in aglyce-564 Cell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc.mic conditions. This suggests that the UPR can contribute to
angiogenesis by enhancing synthesis of both VEGF and non-
VEGF targets.
Apoptotic and Anti-angiogenic Response Driven by ER
Stress
The UPR balances cell survival and cell death and can thus also
negatively impact vascular development and growth. In addition
to adapting rates of translation to fulfill the needs of the tissue,
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ways. This UPR-based mechanism allows for elimination of cells
that are unable to provide proper protein production and folding
and hence are unable to partake in the adaption of tissue to a
stressful situation. Notably, the activation of TRAF2-JNK by
IRE1a (Urano et al., 2000) (Figure 1B) can trigger cytochrome
c-mediated apoptotic pathways by phosphorylating specific
Bcl2-related proteins, such as Bim or Bcl-2 (Puthalakath et al.,
2007; Yamamoto et al., 1999), or activate caspase-12 (in mice)
(Yoneda et al., 2001). In addition, sustained activation of the
PERK-ATF4 axis leads to the accumulation of the transcription
factor CHOP. As discussed above, CHOP triggers expression
of GADD34 and, under irremediable cell stress, promotes the
protein synthesis required for apoptotic cell death (Marciniak
et al., 2004).
Notably, protein oversynthesis can itself become a driver of ER
stress-induced apoptosis. A potential mechanism in this process
involves induction of protein synthesis machinery, including 11
aminoacyl-tRNA synthetases (Aars, Lars, Yars, Sars, Wars,
Vars, Nars, Mars, Gars, Iars, and Eprs) and four initiation factors
(Eif2s2, Eif3c, Eif4g2, and Eif5) by ATF4 and CHOP (Figure 1A)
(Han et al., 2013). Increased protein production and folding in
the ER consequently depletes ATP stores and causes oxidative
stress, leading to cell death (Han et al., 2013). In addition, pro-
apoptotic programs initiated by CHOP involve outer mitochon-
drial membrane permeabilization through downregulation of
Bcl2 (McCullough et al., 2001), induction of oxidative stress
through upregulation of ER oxidoreductin-1a (ERO1a) (Tabas
and Ron, 2011), and upregulation of DR5 and activation of
caspase-8 (Lu et al., 2014) Altogether, crosstalk between the
PERK-ATF4 and IRE1a pathways, as well as the duration of ER
stress, determine whether the final cellular outcome will be
survival or apoptosis.
Similar to the apoptotic programs initiated by the UPR, ER
stress can also drive an anti-angiogenic response (Figure 3B).
For example, under physiological stress, mildly ischemic retinal
neurons produce the neuroimmune guidance cue, netrin-1,
which has the propensity to trigger a pro-reparative/pro-angio-
genic program in retinal microglia. Yet, in retinopathy under con-
ditions of severe hypoxia, ischemic neurons trigger both IRE1a
and PERK pathways (Binet et al., 2013). Of these, IRE1a, through
RIDD activity, degrades netrin-1 and hence impedes proper
revascularization of the ischemic retina (Binet et al., 2013) (see
below).
Comparably, CHOP is induced by all three branches of the
UPR and transcriptionally represses endothelial nitric oxide syn-
thase (eNOS) (Loinard et al., 2012). In health, nitric oxide produc-
tion by eNOS promotes angiogenic sprouting and regulates
blood flow (Fukumura et al., 2001). Binding of CHOP to a region
spanning positions 757–1222 bp or 2843–3086 bp of the eNOS
promoter inhibits its expression (Loinard et al., 2012). An
example of CHOPs negative regulation of vascularization is illus-
trated in CHOP/ mice, which show increased postnatal
ischemia-induced neovascularization (Loinard et al., 2012), sug-
gesting that under severe or prolonged ER stress, CHOP drives
an anti-angiogenic response. Taken together, ER stress path-
ways regulate angiogenesis by either promoting vascularization
under milder conditions of ER stress and prevent vascular
growth under harsher conditions, possibly to segregate unsal-vageable tissue (see below). Table 1 summarizes the current
studies describing how the UPR drives either pro- or anti-angio-
genic programs in different contexts.
Angiogenic Pathways Employ Components of the UPR
Independently of ER Stress
As described above, ER stress can have context-dependent and
dichotomous effects on angiogenesis, where it can either induce
or repress expression of pro-angiogenic genes. In addition, new
evidence suggests that angiogenic programs can themselves
trigger UPR pathways independently of accumulation of
unfolded proteins in the lumen of the ER (Figures 3C and 3D).
For example, short-term exposure (1 hr) to VEGF has been re-
ported to provoke XBP-1 splicing in cultured human umbilical
vein endothelial cells (HUVEC) (Zeng et al., 2013) and human
retinal endothelial cells (Liu et al., 2013a). More precisely, upon
VEGF-induced internalization of kinase-insert domain receptor
(KDR/ VEGFR2), the complex interacts with IRE1a and unspliced
XBP-1 to facilitate XBP-1 splicing (Zeng et al., 2013) (Figure 3C).
Within this VEGF-induced pro-angiogenic context, spliced
XBP-1 contributes to endothelial growth and proliferation by
activating the Akt/glycogen synthase kinase (GSK)/b-catenin/
E2F2 pathways (Zeng et al., 2013). This signaling node is further
modulated by negative regulation of XBP-1 expression following
binding of miR-214 to its 30 UTR (Duan et al., 2015).
Similarly, the PERK and ATF6 branches of the UPR are acti-
vated following stimulation of endothelial cells by VEGF and pro-
mote survival and angiogenesis, independent of accumulation of
unfolded proteins or perturbations in calcium homeostasis in the
ER (Karali et al., 2014). The pro-angiogenic effects of PERK and
ATF6 occur via a phospholipase C (PLC)g-mammalian target of
rapamycin complex 1 (mTORC1)-Akt-dependent cascade up-
stream of the UPR and do not require dissociation of GRP78
(Karali et al., 2014) (Figure 3D). Together, these studies suggest
that the classical pro-angiogenic cues can utilize the signaling
machinery of the UPR independent of ER stress to ensure endo-
thelial survival and to promote angiogenesis.
UPR Pathways in Pathological Angiogenesis
In adults, mature vessels are mostly quiescent and typically only
sprout in specific conditions such as during tissue repair, to
accommodate increased muscle mass following exercise or
increased adiposity. Abnormal vessel growth in adults is associ-
ated with several pathologies such as cancer, ischemic retinop-
athies and inflammatory conditions. Below, we describe the
contribution of ER stress to tumor angiogenesis, retinopathy as
well as atherosclerosis.
UPR in Tumor Angiogenesis
To date, much of the associations drawn between ER stress and
tumor angiogenesis occur via paracrine mechanisms, where the
UPR originates in cancerous cells and impacts vascularization.
The low pH, oxygen-free, and glucose-deprived tumor microen-
vironment is conducive for activation of ER stress pathways that
are harnessed by cancer cells to sustain their survival. Solid tu-
mor expansion is favored with an elevated supply of energy
through the high influx of nutrients and oxygen provided through
tumor-associated neovessels (Hanahan andWeinberg, 2011). In
addition, tumor-associated blood vessels allow for dissemina-
tion of metastases. As a result, several anti-angiogenic therapiesCell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc. 565
Table 1. UPR Pathways Trigger Pro- and Anti-angiogenic Outcomes in Various Settings
Pathways Activated Models Used Inducers of ER Stress References
Pro-angiogenic Effects of ER Stress
ATF6, PERK-ATF4, IRE1a-
XBP1s
prostate cancer, liver cancer, pancreatic
b cell lines
chemical inducers (Tg, Tm) Ghosh et al., 2010
IRE1a-XBP-1 s-Crystallin
alpha B, ATF6
retinal microvascular endothelial cells,
laser-induced CNV, OIR models
VEGF, hyperglycemia, oxidative stress Liu et al., 2013a
PERK-eIF2 a-ATF4 human retinal pigment epithelial cell line arsenite-oxidative stress Roybal et al., 2005
IRE1a-XBP1s, PERK-ATF4 Daoy human medulloblastoma cell line,
C6 rat glioma cell line
hypoxia, chemical inducers (Tg, Tm) Pereira et al., 2010
PERK-eIF2a-ATF4 Human carotid artery, aortic, uterine
microvascular cells, umbilical vein
endothelial cells
oxidized phospholipids Afonyushkin et al., 2010;
Oskolkova et al., 2008
PERK-eIF2a-ATF4 head and neck squamous cell carcinoma,
breast cancer and glioma cell lines, tumor
xenografts
glucose deprivation Wang et al., 2012
IRE1a glioma cell lines, intracerebral implantation,
chicken CAM model
dominant-negative transgene expression
of IRE1a
Auf et al., 2010
PERK-eIF2 a tumor xenografts inhibition of tumor vascularization with
the PERK inhibitor GSK2656157
Atkins et al., 2013
Anti-angiogenic Effects of ER Stress
IRE1a-RIDD, PERK OIR-retinal ganglion cells hypoxia Binet et al., 2013
CHOP hind-limb ischemia, post-natal
neovascularization, diabetic post-ischemic
vessel growth
oxidative stress-hypoxia Loinard et al., 2012
CREB3L1 rat mammary tumor model ectopic expression in highly metastatic
cell lines
Mellor et al., 2013
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Reviewhave been approved that function through sequestration of
VEGF (bevacizumab, renabizumab, and aflibercept) or by pre-
venting VEGF signaling (sorafenib, sunitib, and pazopanib)
(Ebos and Kerbel, 2011).
Regrettably, they only modestly prolong progression-free sur-
vival and overall survival in cancer patients (Ebos and Kerbel,
2011). Additionally, concerns have been raised regarding
chemotherapy resistance, increased metastatic potential (Loges
et al., 2010), and rebound tumor growth with use of anti-angio-
genic therapies. Many hypotheses have been put forward to
explain the inefficacy of anti-angiogenic therapies, such as the
ability of the tumor to secrete its own distinct pro-angiogenic
molecules, attract potent immune cells (e.g., tumor-associated
macrophages), and recruit bone marrow-derived leucocytes
with pro-angiogenic potential or an enrichment in resistant can-
cer stem cells (Welti et al., 2013). Altogether, these mechanisms
enhance vascular supply.
Elements underlying the resistance to anti-angiogenic thera-
pies might be attributed to ER stress originating from the
cancerous cellswithin the tumor itself. Cancer cells activate path-
ways of ER stress to counterbalance increased protein malfold-
ing and to adapt to new metabolic conditions. Several studies
point to a direct role of the UPR in tumor angiogenesis, and ER
stress can thus directly compete with anti-angiogenic therapeu-
tic strategies. For example, the PERK-ATF4 axis becomes acti-
vated in tumors under extreme hypoxic conditions and may be
part of a fundamental mechanism to help tumors adapt to
hypoxic stress through translational control of pro-angiogenic
factors, such as VEGF (Fels and Koumenis, 2006), type 1566 Cell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc.collagen-inducible protein (VCIP), or matrix metalloproteinase
13 (MMP13) (Blais et al., 2006). In line, tumors derived from
K-Ras-transformed Perk/ embryonic fibroblasts show
severely compromised tumor vascularization (Blais et al., 2006),
and PERK-deficient mice have impaired growth of b cell insuli-
noma tumors as a consequence of reduced tumor vasculariza-
tion (Gupta et al., 2009). Moreover, IRE1a also drives formation
of tumor vascular networks (Auf et al., 2010; Drogat et al., 2007)
as expression of a dominant-negative form of IRE1a (dnIRE1a)
compromisesproduction of VEGFandpro-angiogenic inflamma-
torymolecules, such as IL-1b, IL-6, and IL-8, resulting in reduced
neovascularization of various xenografted tumors, such as im-
planted gliomas (Auf et al., 2010; Drogat et al., 2007) or lung car-
cinomas (Drogat et al., 2007). The pro-angiogenic response
driven by IRE1a could be secondary to XBP-1 splicing as overex-
pression of a C-terminal-deleted IRE1a (i.e., with compromised
endoribonuclease function) impedes blood vessel formation in
human pancreatic adenocarcinomas (Romero-Ramirez et al.,
2009). Similarly, deficiency in the ER chaperone GRP78 impedes
tumor growth byaffecting angiogenesis (Donget al., 2008) and, in
a number of cancers, such as that of breast, liver, gastric, esoph-
agus, brain, prostate, head and neck, and melanoma, tumor
aggressiveness, and recurrence correlatewith increased synthe-
sis of the ER chaperone GRP78 (Ni et al., 2011).
Modulating ER stress may thus compromise the adaptive
response of the tumor and provide an alternative or adjunct ther-
apeutic avenue to counter aggressive cancers. For example, co-
treatment of aggressive triple-negative breast cancer (a form of
breast cancer in which tumor cells do not express the genes
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short hairpin RNA (shRNA) against XBP-1 and chemotherapy in-
hibits or delays tumor relapse (Chen et al., 2014). In these tu-
mors, increased splicing and activation of XBP-1 by IRE1a favors
expansion of tumor-initiating CD44high CD24low cells (Chen et al.,
2014). Interestingly, dnIRE1a tumors show lower expression of
hypoxia-inducible factor-1a (HIF1a) (Drogat et al., 2007).
HIF-1a, much like pathways activated by ER stress, modulates
a collection of genes with overlapping functions that permit the
cell to adapt to metabolic insufficiencies and hypoxic environ-
ments (Koh and Powis, 2012) and a large number of genes
involved in angiogenesis, energy metabolism, erythropoiesis,
cell proliferation, and vascular remodeling and is amajor contrib-
utor of tumor growth (Coulon et al., 2010). UPR signaling may
enhanceHIF1a activity by increasing its phosphorylation (Pereira
et al., 2014). Notably, XBP-1 influences HIF-1a activity through
formation of a transcriptional complex in chemoresistant triple-
negative breast cancer cells (Chen et al., 2014). The XBP-1-
HIF-1a complex is important for tumor growth and influences
relapse by controlling subsets of transcription targets, including
genes involved in angiogenesis, such as VEGF, pyruvate dehy-
drogenase kinase 1 (PDK1), or glucose transporter 1 (GLUT1)
(Chen et al., 2014).
Beyond the angiomodulatory properties of ER stress initiated
by the cancer cell, pathways of the UPR are activated directly
within tumor vasculature and partake in tumor growth. For
example, GRP78 relocalizes from the ER to the plasma mem-
brane of endothelial cells in tumor vessels upon induction of
ER stress or secondary to a rise in VEGF levels (Katanasaka
et al., 2010; Lee, 2014). Plasma membrane-associated GRP78
partners with T-cadherin in tumor endothelial cells to favor pro-
survival signaling via PI3kinase/Akt (Philippova et al., 2008) and
thus directly contributes to tumor angiogenesis (Lee, 2014).
Conversely, evidence exists for a context-dependent ER
stress-mediated inhibition of tumor progression. For example,
cyclic AMP-responsive element binding protein 3-like 1
(CREB3L1), the human and rat homolog of the b/zip motif-con-
taining transcription factor, OASIS, is shuttled from the ER to
the Golgi and processed to its active form under conditions of
ER stress. Unlike classical UPR pathways, such as IRE1a or
PERK, which are utilized by cancer cells to increase resistance
to environmental stressors (Drogat et al., 2007). CREB3L1 binds
promoter regions of angiogenic genes, such as prostaglandin E
synthase, fibroblast growth factor-binding protein 1, or chemo-
kine (C-X-C motif) ligand 10 (CXCL10), and represses their tran-
scription. Hence, induction of CREB3L1 will be detrimental for
tumor growth, in part by compromising tumor angiogenesis
(Mellor et al., 2013). CREB3L1 could thus work against other
pathways of the UPR, such as ATF4 and IRE1a, which drive
expression of pro-angiogenic genes but can also trigger pro-
apoptotic arms of the UPR (Sano and Reed, 2013).
Overall, tumor progressionmay initially rely on pathways of the
UPR, such as PERK and IRE1a, in its early stages to accommo-
date increased protein folding and to help adapt to conditions of
low glucose or O2 by driving a pro-angiogenic response. Later,
silencing pro-apoptotic arms of the UPR, such as CREB3L1 or
CHOP, would ensure maintenance of tumor vasculature (Mellor
et al., 2013) and might be beneficial for tumor survival (Sano
and Reed, 2013).UPR in Proliferative Retinopathies
Proliferative retinopathies, such as retinopathy of prematurity
(ROP) and proliferative diabetic retinopathy (PDR), are the lead-
ing causes of blindness in pediatric and working-age popula-
tions (Gilbert et al., 1997; Kempen et al., 2004). Both conditions
are characterized by an initial phase of microvascular degenera-
tion and a second phase of pathological pre-retinal neovascula-
rization originating from the ischemic retina, which invades
physiologically avascular zones of the eye and causes loss of
sight (Chen and Smith, 2007; Cheung and Wong, 2008; Smith,
2008; Sapieha et al., 2010a).
In health, retinal vasculature develops until term at 40 weeks.
Hence, infants born prematurely have incomplete retinal vascu-
larization. Blood vessels are further compromised by oxygen
toxicity (through reactive oxygen species) secondary to ventila-
tion at high partial pressure of oxygen (PaO2) to overcome pul-
monary insufficiency in these infants. In addition, ventilation at
high concentrations of oxygen leads to suppression of oxygen-
regulated angiogenic factors, such as VEGF and Epo (Sapieha
et al., 2010b). Furthermore, physiological vascularization of the
immature retina is affected by the absence of maternally trans-
ferred vaso-potentiating and vaso-protective factors, such as
long chain u-3 polyunsaturated fatty acids (Connor et al.,
2009; Sapieha et al., 2011; Stahl et al., 2010) and insulin growth
factor-1 (IGF-1) (Smith et al., 1999).
In diabetic retinopathy (DR), unchecked blood glucose levels
can eventually lead to vascular occlusion, heightened vascular
permeability, microvascular degeneration, and, consequently,
areas of non-perfusion (Hammes et al., 2011). DR can be initially
asymptomatic, and vision loss is triggered primarily by diabetic
macular edema, vitreal hemorrhages, and, in later proliferative
phases, tractional retinal detachment. While much effort has
been invested in elucidating the mechanisms that lead to mi-
cro-vascular degeneration in DR, a clear patho-mechanism
has yet to be established. Correlations have been made with
advanced glycation end products (Brownlee et al., 1984), protein
kinase C activation (Ways and Sheetz, 2000), heightened inflam-
mation (Adamis and Berman, 2008; Antonetti et al., 2012; Jous-
sen et al., 2004), oxidative stress (Ways and Sheetz, 2000),
elevated neuronal derived factors, such as Semaphorins (Cerani
et al., 2013), and initial onset of acute intensive insulin therapy.
A role for ER stress and its pathways in proliferative retinopa-
thies is starting to emerge. Branches of the UPR, such as IRE1a,
PERK, and ATF6, become activated in a mouse model of
oxygen-induced retinopathy (OIR), which yield areas of retinal
ischemia analogous to those observed in ROP and PDR (Binet
et al., 2013; Li et al., 2009; Liu et al., 2013a). Similarly, pathways
of the UPR are activated in retinas of mice subjected to models
of diabetes (Li et al., 2009). A pronounced ER stress response is
triggered in central neurons within avascular zones (Binet et al.,
2013). Under sustained hypoxia, an IRE1a-RIDD pathway pro-
motes degradation of the neurovascular/neuroimmune guidance
cue netrin-1. Netrin-1 drives secretion of VEGF from microglia in
the vicinity of growing vascular tip cells (Figure 2B), and hence
cleavage of netrin-1 mRNA impedes revascularization of avas-
cular retinal zones. Hence, activation of the IRE1a arm of the
UPR can prevent reparative angiogenesis in severe cases of
hypoxia by disrupting vital neuroimmune crosstalk (Binet et al.,
2013). Therefore, during extended periods of hypoxia, the UPRCell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc. 567
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tion, possibly to redirect remaining metabolic stores to less
affected areas of the retina (see below).
Furthermore, dietary u-3 long-chain polyunsaturated fatty
acids have been shown to suppress pathological pre-retinal neo-
vascularization in OIR (Connor et al., 2009; Sapieha et al., 2011;
Stahl et al. 2010). Diets rich in u-3 long-chain polyunsaturated
fatty acids raise serum adiponectin levels, which inversely corre-
late with ROP severity (Fu et al., 2015). In OIR, ER stress within
white adipose tissue leads to a drop in circulating bioactive
high molecular weight adiponectin and hence poor prognosis.
Administration of dietary u-3 fatty acid was found to reverse
activation of p-EIF2a or CHOP in adipocytes and consequently
alleviate pathological retinal neovascularization in part through
adiponectin synthesis and also through increased formation of
bioactive high molecular weight forms (Fu et al., 2015). There-
fore, systemic ER stress may remotely affect vascularization of
peripheral tissues by impacting protein hormone synthesis and
their assembly into bioactive forms.
UPR in Atherosclerosis
In contrast to cancer and ischemic retinopathies, which are char-
acterized by pathological angiogenesis, atherosclerosis primar-
ily affects endothelial cell function and health. Chronic exposure
to several activators of the UPR, such as hyperglycemia, shear
stress, or hypercholesterolemia, provoke arterial endothelial
damage, monocyte adhesion, inflammatory reactions, and
formation of subendothelial deposits, ultimately leading to
atherosclerosis (Zhou and Tabas, 2013). A role for ER stress is
suggested given the upregulation or activation of several effec-
tors of the UPR, such as IRE-1a, ATF-6, and XBP-1, following
disturbed blood flow in atherosusceptible regions, such as
curved or branching points of the aorta (Civelek et al., 2009; Fea-
ver et al., 2008; Zeng et al., 2009). Here, the UPR effector un-
spliced XBP-1 is initially protective and promotes EC survival
by shielding the endothelium from oxidative stress injury (Martin
et al., 2014). When disturbed flow persists, sustained ER stress
leads to XBP-1 splicing and triggers a detrimental pro-apoptotic
response (Zeng et al., 2009).
Macrophage polarization, apoptosis, and efferocytosis are
central in the pathogenesis of atherosclerosis (Tabas, 2010),
and the involvement of the UPR in these processes has been
well demonstrated (Tabas, 2009). Interestingly, ER stress orig-
inating from non-hematopoietic cells, such as endothelial cells,
is also thought to play a significant role in this process. This is
suggested by a series of bone marrow transfer experiments
from CHOP-deficient mice, in which the authors detail the
cardinal role of host ER stress from vascular and other cells
with a lesser contribution of ER stress originating from
hematopoietic cells (Gao et al., 2011). Thus, the UPR partakes
in regulating endothelial cell homeostasis in regions prone
to atherosclerosis by initially providing a protective, pro-
survival period, and under conditions of chronic stress, contrib-
uting to endothelial cell death and defective macrophage
efferocytosis.
Segregation of Vascular Networks by ER Stress-
Dependent Pathways
In a healthy tissue, vascular supply must be tightly coupled to
metabolic demand. When in a systemic energy crisis, such as568 Cell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc.hemorrhagic, cardiogenic, or spinal shock, systemic blood
flow must be rapidly deviated toward vital organs to ensure
survival. A parallel, yet more protracted, process may occur
during sustained ischemia in the CNS to deviate metabolic
stores to cells in less affected areas that are more likely to
survive. For example, when driven beyond the threshold of re-
covery, severely ischemic neurons produce vaso-repulsive
factors, likely in an attempt to shunt metabolic resources from
perishing unsalvageable ischemic tissue toward less affected
regions of the CNS (Sapieha, 2012). Regenerating vascular
networks into unsalvageable tissue would be energetically
inefficient.
In the retina, for example, hypoxia/ischemia are undeniably
major promoters of angiogenesis (Carmeliet, 2001), yet when
hypoxia persists and neurons are driven beyond a metabolic
threshold, they revert to producing classical vascular and
neuronal repulsive cues, such as Semaphorin3A (Joyal et al.,
2011) and Semaphorin3E (Fukushima et al., 2011), and activate
pathways of the UPR (Binet et al., 2013). Induction of vaso-repul-
sive cues, such as Semaphorins, by ischemic retinal neurons
may be a generalized event in the CNS as levels of
Semaphorin3A rise following ischemic stroke (Carmichael,
2006; Fujita et al., 2001) and localize to regions adjacent the
zone of infarct and necrotic core (Carmichael et al., 2005). In
addition, levels of Semaphorin3A rise in neurons near the site
of spinal cord injury lesion (De Winter et al., 2002). The induction
of repulsive guidance cues consequent to CNS injury is contem-
poraneous with a period of vascular remodeling and axonal
sprouting, suggesting an attempt by the profoundly injured neu-
rons to deviate both regenerating neuronal and vascular sprouts
away from zones of severe damage.
Similarly, ER stress may also be a mechanism through which
cells in damaged or diseased tissue adjust blood supply.
Hypoxia is an activator of the UPR in several ischemic condi-
tions, such as ischemic heart disease, cerebral ischemia, and
ischemic retinopathies (Tajiri et al., 2004; Binet et al., 2013).
According to the intensity and duration, ER stress can promote
divergent effects (see Figure 4A). Under mild ER stress, all three
branches of the UPR increase expression of VEGF and thus
assure appropriate tissue vascular supply (Ghosh et al., 2010;
Figure 3A) and local vascular irrigation. Conversely, sustained
activation of ER stress pathways, and specifically IRE1a (Binet
et al., 2013), may provide the tissue with the appropriate enzy-
matic machinery to shift from a pro-angiogenic program of
vascular regeneration to one that is angiostatic.
The process of tissue segregation would allow for redistribu-
tion of oxygen and nutrients to sectors of tissue that would
preferentially benefit. In this regard, elegant studies with ki-
nase-dead mutants of IRE1a or pseudokinase mutants of
IRE1a with crippled endoribonuclease activity established that
the pro-apoptotic activity of IRE1a requires both its RNase and
phosphotransfer activity and proceeded independently of
XBP-1. Conversely, cytoprotection relies on active RNase activ-
ity and XBP-1 (Han et al., 2009). These divergent effects of ER
stress may also operate in the CNS to correctly drive a pro-
angiogenic response, where tissue is under a remediable level
of hypoxic stress. ER stress pathways may therefore collectively
act as sensors of global tissue health and ensure proper pairing
of cell function with blood supply.
Figure 4. Potential Therapeutic Modulation of UPR Signaling for Treatment of Diseases with Heightened Angiogenesis
(A) A conceptual diagram showing how low levels of ER stress promote multimerization of IRE1a and thus activation of pro-angiogenic effector pathways
(bottom). Conversely, high ER stress promotes angiostatic and anti-angiogenic programs (top).
(B) Pathways of the UPR offer novel therapeutic targets for tumor angiogenesis and proliferative retinopathies. These include inhibitors of PERK (GSK2656157)
and IRE1a (4m8C, STF-083010) and neutralizing antibodies to membrane or soluble forms of GRP78 (thus far reported for tumor angiogenesis). Chemical
chaperones, such as PBA, recombinant adeno-associated virus (rAAV)-expressing p58IPK (a negative regulator of PERK), or shRNAs against IRE1a, represent
novel experimental strategies for pathological angiogenesis in the eye.
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Angiogenesis
With ever-increasing insight into how various arms of the UPR
contribute to a range of diseases, there is growing interest in
devising therapeutic strategies aimed at interfering with ER
stress. In this regard, several classes of small-molecule drugs
have been designed over the last years to modulate UPRsignaling. These can be classified into (1) repressors of the
pro-apoptotic arm of the UPR for treatment of chronic diseases
(Moreno et al., 2013; Ozcan et al., 2006) or (2) suppressors of
the UPR’s pro-survival properties for treatment of cancer
(Atkins et al., 2013; Mimura et al., 2012). These compounds
include (1) chemical chaperones (4-phenylbutyrate [PBA] and
Tauroursodeoxycholic acid), (2) ERAD inhibitor (eeyrestatin),Cell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc. 569
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hibitors (PDIA1 inhibitor), (4) Salicylaldehyde family of IRE1a
RNase inhibitor (4m8C, STF-083010, MKC-3946), (5) PERK
signaling modulators (GSK260614/GSK2656157, salubrinal),
and (6) GRP78-neutralizing antibodies. For a detailed overview
on modes of action, refer to Cao and Kaufman (2013), Hetz
et al. (2013), and Maly and Papa (2014).
To date, preclinical data on the efficacy of UPR inhibitors in
modulating angiogenesis is trickling in, shows promise, and
establishes proof of concept. For example, GSK2656157, a
small-molecule inhibitor of PERK kinase, displays anti-angio-
genic and anti-tumoral activity toward pancreatic adenocarci-
noma-derived tumor xenografts (Atkins et al., 2013; Axten
et al., 2013). Correspondingly, dynamic contrast-enhanced
MRI of GSK2656157-treated tumors revealed lower perfusion
rates and a reduction in the expression of the endothelial cell
marker vanWillebrand factor (vWF) (Atkins et al., 2013).
Tumor endothelial cells display specific functional and
morphological properties, including overexpression of GRP78
(McFarland et al., 2009; Pyrko et al., 2007; Virrey et al., 2008),
which confers increased resistance to apoptosis and chemo-
therapy. In line, tumor growth in GRP78 heterozygous mice is
slowed due to reduced vascularization, whereas vessel growth
in non-cancerous tissue remains unaffected (Dong et al.,
2008). Therefore, pharmacological disruption of GRP78 sig-
naling may represent an attractive anti-angiogenic strategy
without affecting physiological angiogenesis (Lee, 2014).
GRP78 is expressed on the surface of proliferating endothe-
lial cells (Davidson et al., 2005) and associates with T-cadherin
to ensure endothelial survival (Philippova et al., 2008). The re-
localization of GRP78 to the plasma membrane is promoted
by hypoxia (Hardy et al., 2008) or exposure to VEGF (Katana-
saka et al., 2010), and signaling through cell-surface GRP78
by angiogenic peptides can trigger proliferation and migration
of endothelial cells (Raiter et al., 2010). In line, treatment with
a high-affinity mouse monoclonal antibody against GRP78
(mab159) impedes tumor growth and decreases tumor vascu-
larization, albeit modestly (Liu et al., 2013b). The same effect
was seen using a polyclonal antibody to GRP78 that depletes
soluble GRP78. Secretion of soluble GRP78 by certain tumor
cell lines confers resistance against the pro-apoptotic effect
of bortezomib, both in tumor and endothelial cells (Kern
et al., 2009). Hence, combining modulators of ER stress with
conventional chemotherapy may help to overcome GRP78-
associated tumor resistance to drugs, such as CPT-11, etopo-
side, temozolomide (Virrey et al., 2008), or bortezomib (Kern
et al., 2009).
Strategies that target the UPR could also be useful to treat
vaso-proliferative disorders of the eye, namely, diabetic reti-
nopathy or retinopathy of prematurity (see above). Current
challenges in this therapeutic space include finding safer alter-
natives to current treatments, such as laser photocoagulation,
which can lead to a loss of peripheral vision (Mohamed et al.,
2007), or limiting photoreceptor toxicity and vitreoretinal
fibrosis observed secondary to anti-VEGF therapies (Kuiper
et al., 2008). In animal models that recapitulate these diseases,
blocking effectors of the UPR, such as ATF4 (Wang et al.,
2013) or IRE1a (Binet et al., 2013), effectively suppresses path-
ological neovascularization. Similarly, intravitreal injection of an570 Cell Metabolism 22, October 6, 2015 ª2015 Elsevier Inc.adeno-associated virus expressing p58IPK, a repressor of
PERK activation, preserves retinal endothelial cell integrity in
a rat model of streptozotocin-induced type I diabetes (Yang
et al., 2011). Administration of p58IPK limits ER stress-induced
inflammation caused by hyperglycemia and thus suppresses
retinal vascular leakage, which represents an early clinical
manifestation of diabetic retinopathy (Hu et al., 2012). With
the success of such pre-clinical studies, further investigation
is warranted to determine if small-molecule drugs interfering
with IRE1a function (STF-083010, 4m8C) or PERK activity
(GSK2606414 or rAAV-p58IPK) are efficacious in retinal
vascular disorders or if they can be used as adjunct therapies
with existing anti-angiogenic treatment paradigms, such as
anti-VEGFs, to prevent pre-retinal neovascularization and
macular edema.
In sum, pharmalogical modulators of the UPR offer prospec-
tive therapeutic avenues to counter pathological angiogenesis
(see the proposed scheme in Figure 4B). The efficacy of many
of these compounds has already been demonstrated in models
of chronic neurodegenerative disease or as anti-tumor chemo-
therapeutic agent (Moreno et al., 2013; Papandreou et al.,
2011). Further pre-clinical and clinical investigation and valida-
tion will be required to determine the merits of UPR modulators
as drugs against pathological angiogenesis or to preserve endo-
thelial function.
Conclusions and Perspectives
From the simplest living organisms, such as protozoa or yeast,
to the most complex mammals, pathways of the UPR have
evolved in parallel with increased energy requirements and
constraints of closed vascular networks and tissue specializa-
tion. Accumulating evidence suggests that the UPR (whether
activated by accretion of misfolded proteins in the ER or inde-
pendently) modulates vascular growth and maintenance and
survival of endothelial cells. Pathways of the UPR provide the
cell with the machinery to rapidly adapt to ever-changing meta-
bolic requirements. They initially confer a survival advantage,
yet when sustained, mediate death. UPR signaling from an
ischemic tissue may initially stimulate its vascularization, and
when driven beyond the threshold of recovery, may orchestrate
its segregation and degeneration. From a therapeutic perspec-
tive, targeting aberrant angiogenesis or normalizing residual
vessels in diseases such as cancer and blinding retinal neovas-
cular conditions, requires novel avenues of exploration given
the relative inefficacy of current anti-angiogenic therapies. In
this regard, exploring the anti-angiogenic properties of selec-
tive small-molecule inhibitors for components of the UPR,
such as the IRE1a endoribonuclease blocker 4m8C or the
PERK kinase inhibitor GSK2606157, is warranted. To date,
approved and exploratory anti-angiogenic treatments rely
largely on ligand neutralization and perturbation of classical
angiogenic signaling pathways. Modulation of ER stress path-
ways may provide attractive stand-alone or adjunct strategies
to counter destructive angiogenesis without sequestering
growth factors, such as VEGF, Epo, or Angiopoietins, which
also play several essential roles in tissue homeostasis. Deci-
phering the interplay between pathways of the UPR and drivers
of vascular growth will provide both valuable fundamental and
therapeutic insight.
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